- Home
- AUTL vs FBRX Comparison
AUTL vs FBRX Comparison
Compare AUTL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.65
HOLD
Current Price
$31.78
Company Overview
Basic Information| Metric | AUTL | FBRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United Kingdom | United States |
| Employees | 647 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 366.5M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AUTL | FBRX |
|---|---|---|
| Price | $1.65 | $31.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.4M | 194.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,120,000.00 | $36,000.00 |
| Revenue This Year | $670.78 | N/A |
| Revenue Next Year | $80.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.11 | $4.91 |
| 52 Week High | $2.70 | $35.62 |
Technical Indicators
Market Signals| Indicator | AUTL | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 56.59 |
| Support Level | $1.27 | $26.58 |
| Resistance Level | $1.74 | $32.12 |
| Average True Range (ATR) | 0.11 | 2.53 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 46.95 | 76.55 |
Price Performance
Historical Comparison AUTL
FBRX
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).